Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-27T14:04:37.808Z Has data issue: false hasContentIssue false
  • English
  • Français

A Controlled Trial of Mitoxantrone in Multiple Sclerosis: Serial MRI Evaluation at One Year

Published online by Cambridge University Press:  18 September 2015

S. Bastianello ,
C. Pozzilli ,
F. D’Andrea ,
E. Millefiorini ,
M. Trojano ,
S. Morino ,
C. Gasperini ,
A. Bozzao ,
M. Gallucci  and
C. Andreula
...Show all authors
S. Bastianello*
Affiliation:
Chair of Neuroradiology
C. Pozzilli
Affiliation:
Department of Neurosciences, University of Rome “La Sapienza”; Chair of Neurology
F. D’Andrea
Affiliation:
Chair of Radiology
E. Millefiorini
Affiliation:
Chair of Neuroradiology
M. Trojano
Affiliation:
Chair of Neuroradiology
S. Morino
Affiliation:
Department of Neurosciences, University of Rome “La Sapienza”; Chair of Neurology
C. Gasperini
Affiliation:
Department of Neurosciences, University of Rome “La Sapienza”; Chair of Neurology
A. Bozzao
Affiliation:
University of Aquila; Chair of Neurology
M. Gallucci
Affiliation:
Department of Neurosciences, University of Rome “La Sapienza”; Chair of Neurology
C. Andreula
Affiliation:
University of Bari; Chair of Neurology
L. Bozzao
Affiliation:
Chair of Neuroradiology
D. Gambi
Affiliation:
University of Chieti
M. Prencipe
Affiliation:
Chair of Radiology
*
Cattedra di Neuroradiologia, Dipartimento di Scienze Neurologiche, Università di Roma “La Sapienza”, Viale dell’Università 30, 00185 Rome, Italy
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

We present the results of a randomized double-blinded placebo controlled, multicenter trial, of low-dose mitoxantrone (MX), after one year, in 25 patients with relapsing-remitting multiple sclerosis, who had serial enhanced magnetic resonance imaging (MRI). Treatment groups were balanced for age, gender, duration of illness and neurological disability. Five of the 13 MX patients and 10 of the 12 placebo patients had exacerbations during treatment (p < 0.02). The mean change in the extended disability status scale was not significantly different between the MX and placebo treatment groups. Serial Gadolinium-DTPA enhanced MRI detected no significant difference between the MX treated and placebo groups in the mean total number of new, enlarging, or Gadolinium-DTPA enhancing lesions; there was a trend toward a reduction of new, enlarging and Gadolinium-DTPA enhancing lesions in MX patients. Despite this ameliorating effect, the results indicate that serial Gadolinium-DTPA enhanced MRI, performed over one year in a limited number of patients, could not provide conclusive evidence for a role of MX therapy in relapsing-remitting multiple sclerosis.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 21 , Issue 3 , August 1994 , pp. 266 - 270
Copyright
Copyright © Canadian Neurological Sciences Federation 1994

References

1.Young, IR, Hall, AS, Pallis, CA, et al. Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet 1981; 2: 1063–1066.CrossRefGoogle ScholarPubMed
2.Lukes, SA, Crooks, LE, Aminoff, MJ, et al. Nuclear magnetic resonance imaging in multiple sclerosis. Ann Neurol 1983; 13: 592–601.CrossRefGoogle ScholarPubMed
3.Gonzales-Scarano, F, Grossman, RI, Galletta, S, Atlas, SW, Silberberg, DH.Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging. Ann Neurol 1987; 21:300–306.CrossRefGoogle Scholar
4.Grossman, RI, Braffman, BH, Brorson, JR, et al. Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology 1988; 169: 117–122.CrossRefGoogle ScholarPubMed
5.Isaac, C, Li, DKB, Genton, M, et al. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology 1988; 38: 1511–1515.CrossRefGoogle ScholarPubMed
6.Miller, DH, Rudge, P, Johnson, G, et al. Serial gadolinium-enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988; 111:927–939.CrossRefGoogle ScholarPubMed
7.Willoughby, EW, Grochowski, E, Li, DKB, et al. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 1989; 25: 43–49.CrossRefGoogle ScholarPubMed
8.Bastianello, S, Pozzilli, C, Bernardi, S, et al. Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. Neurology 1990; 40:591–595.CrossRefGoogle ScholarPubMed
9.Kermode, AG, Tofts, PS, Thompson, AJ, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 1990; 40: 229–235.CrossRefGoogle ScholarPubMed
10.Harris, JO, Frank, JA, Patronas, N, McFarlin, DE, McFarlan, HF.Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991; 29:548–555.CrossRefGoogle ScholarPubMed
11.McFarland, HF, Frank, JA, Albert, PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992; 32: 758–766.CrossRefGoogle ScholarPubMed
12.Kappos, L, Stadt, D, Ratzka, M, et al. Magnetic resonance imaging in the evaluation of treatment in multiple sclerosis. Neuroradiology 1988; 30: 299–302.CrossRefGoogle ScholarPubMed
13.Miller, DH, Barkhof, F, Berry, I, et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerned action guidelines. J Neurol Neurosurg Psychiatry 1991; 54: 683–688.CrossRefGoogle Scholar
14.Miller, DH, Thompson, AJ, Morrissey, SP, et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992; 55: 450–453.CrossRefGoogle ScholarPubMed
15.Fidler, JM, Quinn De Joj, S, Smith III, FR, Gibbons, JJ.Selective immunomodulation by the antineoplastic agent mitoxantrone. Non-specific adherent suppressor cell derived from mitoxantrone treated mice. J Immunol 1986; 136: 2747–2754.CrossRefGoogle Scholar
16.Fidler, JM, Quinn De Joj, S, Gibbons, JJ.Selective immunomodulation by the antineoplastic agent mitoxantrone. Suppression of B lymphocyte function. J Immunol 1986; 137: 727–732.CrossRefGoogle ScholarPubMed
17.Levine, S, Saltzam, A.Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J Neuroimmunol 1986; 13: 175–181.CrossRefGoogle ScholarPubMed
18.Gonsette, RE, Demonty, L.Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology 1990; 40 (Suppl 1): 261.Google Scholar
19.Kappos, L, Gold, R, Kunstler, E, et al. Mitoxantrone (MX) in the treatment of rapidly progressive multiple sclerosis: a pilot study with serial gadolinium (GD)-enhanced MRI. Neurology 1990; 40 (Suppl 1): 261.Google Scholar
20.Noseworthy, JH, Lee, D, Penman, M, et al. A phase II evaluation of mitoxantrone HC1 in the treatment of progressive multiple sclerosis. Neurology 1991; 41 (Suppl 1): 146.Google Scholar
21.Noseworthy, JH, Hopkins, MB, Vandervoort, MK, et al. An opentrial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993; 43: 1401–1406.CrossRefGoogle ScholarPubMed
22.Paty, D, Willoughby, E, Whithaker, J.Assessing the outcome of experimental therapies in multiple sclerosis patients. In: “Treatment of Multiple Sclerosis. Trial Design, Results and Future Perspectives.” Rudick, RA, Goodkìn, DE, eds. Springer-Verlag, Germany 1992: 47–90.CrossRefGoogle Scholar
23Poser, CM, Paty, DW, Scheinberg, L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13:227–231.CrossRefGoogle ScholarPubMed
24.Kurtzke, JF.Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1442–1452.CrossRefGoogle ScholarPubMed
25.Goodkin, DE, Ross, JS, Vanderbrug Medendorp, S, Konecsni, J, Rudick, RA.Magnetic resonance imaging lesion enlargement in multiple sclerosis. Disease-related activity, chance occurrence, or measurement artefact? Arch Neurol 1992; 49: 261–263.Google ScholarPubMed
26.McDonald, WI.The dynamics of multiple sclerosis. J Neurol 1993; 240: 28–36.CrossRefGoogle ScholarPubMed
27.Kurtzke, JF.Neuroepidemiology. Part II: assessment of therapeutic trials. Ann Neurol 1986; 19: 311–319.CrossRefGoogle ScholarPubMed
28.Weinshenker, BG, Rice, GPA, Noseworthy, JH, et al. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 1991; 114: 1057–1067.CrossRefGoogle ScholarPubMed
29.Matthews, WB, Matthews, WC, eds. McAlpine’s Multiple Sclerosis, 2nd ed. Edinburgh, Churchill Livingstone, 1991.Google Scholar
30.Thompson, AJ, Kermode, AG, Wicks, D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991; 29: 53–62.CrossRefGoogle ScholarPubMed